ARQT - Arcutis lead product undergoes FDA review for label expansion
2023-11-29 15:09:18 ET
More on Arcutis Biotherapeutics
- Arcutis Biotherapeutics: Almost There, But Needs Some Fine-Tuning
- Arcutis Biotherapeutics, Inc. (ARQT) Q3 2023 Earnings Call Transcript
- Arcutis Biotherapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation
- Jones Research downgrades Arcutis to hold, cites loan agreement
- Mizuho cuts Articus to neutral, cites lower-than-expected prescriptions
For further details see:
Arcutis lead product undergoes FDA review for label expansion